Physician profile
Gregory Stuart Grant
NPI 1629166004
$3,990.83
in general payments reported to CMS, 2019-2025
27 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,866 · 2020: $1,536 · 2021: $293 · 2024: $149 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $480.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $410.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $339.86 | 2019-2025 | Spravato |
| Lilly USA, LLC | $319.74 | 2019-2021 | |
| Astellas Pharma US INC | $296.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.77 | 2019-2021 | |
| Pfizer INC. | $285.08 | 2019-2021 | |
| Amarin Pharma, INC. | $195.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $191.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $143.78 | 2019-2021 | |
| Allergan, INC. | $123.53 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $121.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.31 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $95.44 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $92.30 | 2019-2020 | |
| Corcept Therapeutics | $76.29 | 2019 | |
| Glaxosmithkline, LLC. | $60.71 | 2020-2021 | |
| Shire North American Group INC | $42.17 | 2019 | |
| Abbvie INC. | $36.98 | 2021 | |
| Amgen INC. | $36.39 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.51 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.38 | 2019 | |
| Biodelivery Sciences International, INC. | $14.80 | 2019 | |
| Tersera Therapeutics LLC | $12.71 | 2019 | |
| Eisai INC. | $12.67 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.